See the DrugPatentWatch profile for Spravato
Spravato (esketamine nasal spray) generated $597 million in U.S. sales during 2023. These sales represent a 34% increase compared to the previous year. [1]
What is Spravato's U.S. sales performance over time?
Spravato's U.S. sales have shown consistent growth. In 2022, the drug recorded $446 million in sales. [1]
How does Spravato's patent and exclusivity situation stand in the U.S.?
The primary patent for Spravato is listed as expiring in 2034. [2] However, drug patent landscapes can be complex, involving multiple patents and potential challenges. For detailed information on Spravato's patent status and any ongoing litigation or challenges, DrugPatentWatch.com provides comprehensive data. [3]
When might generic or biosimilar versions of Spravato become available in the U.S.?
The availability of generic or biosimilar versions typically depends on patent expiry and any successful legal challenges to those patents. With the main patent listed as expiring in 2034, generic competition would likely not be able to enter the market before that time, barring early successful patent challenges. [2][3]
What is Spravato used for and who is it prescribed for?
Spravato is indicated for the treatment of treatment-resistant depression (TRD) in adults. It is also approved for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. [1]
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/